The goal of this activity is to improve the competence and performance of learners to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for their patients with AML.

 

Clinicians need to be informed about therapeutic advances and necessary supportive care precautions to aid in their efficacious and safe incorporation into clinical practice for the appropriate AML patient subpopulations. 
Recent advances have led to rational drug development as new therapeutically actionable molecular targets have emerged. It is important for clinicians to be aware of how to incorporate these novel treatment options into clinical practice in ways that achieve meaningful patient outcomes, as well as best practices for providing supportive care and patient education.
Advances in the molecular understanding of acute myeloid leukemia (AML) has enhanced risk stratification and optimized therapeutic strategies. However, there is still a need for improved therapeutic strategies to combat AML disease progression, especially in older patients. Informing clinicians about therapeutic advances and necessary supportive care precautions will aid in their efficacious and safe incorporation into clinical practice for the appropriate AML patient subpopulations.
The goal of this activity is to improve and accelerate the awareness, understanding, and integration of current best practices in the treatment of AML.
Recent advances have led to rational drug development as new therapeutically actionable molecular targets have emerged. It is important for clinicians to be aware of how to incorporate these novel treatment options into clinical practice in ways that achieve meaningful patient outcomes, as well as best practices for providing supportive care and patient education.

The goal of this activity is to improve and accelerate the awareness, understanding, and integration of current best practices in the treatment of AML.

 

Provided by the National Comprehensive Cancer Network in collaboration with Clinical Care Options, LLC

There is a need for improved therapeutic strategies to combat acute myeloid leukemia (AML) disease progression.

Pages

Subscribe to RSS - Acute Myelogenous Leukemia